Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma.

Publikation

Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma.

Wissenschaftlicher Artikel/Review - 01.06.2023

Gaissler Andrea, Bochem Jonas, Spreuer Janine, Ottmann Shannon, Martens Alexander, Amaral Teresa, Wagner Nikolaus, Claassen Manfred, Meier Friedegund, Terheyden Patrick, Garbe Claus, Eigentler Thomas Kurt, Weide Benjamin, Pawelec Graham, Wistuba-Hamprecht Kilian

Zitation

Gaissler A, Bochem J, Spreuer J, Ottmann S, Martens A, Amaral T, Wagner N, Claassen M, Meier F, Terheyden P, Garbe C, Eigentler T, Weide B, Pawelec G, Wistuba-Hamprecht K. Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma. J Immunother Cancer 2023; 11

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

J Immunother Cancer 2023; 11

Veröffentlichungsdatum

01.06.2023

eISSN (Online)

2051-1426

Kurzbeschreibung/Zielsetzung

The need for reliable clinical biomarkers to predict which patients with melanoma will benefit from immune checkpoint blockade (ICB) remains unmet. Several different parameters have been considered in the past, including routine differential blood counts, T cell subset distribution patterns and quantification of peripheral myeloid-derived suppressor cells (MDSC), but none has yet achieved sufficient accuracy for clinical utility.